Rebuilding the Intestine. Restoring Lives.
Pioneering regenerative therapy for Short Bowel Syndrome (SBS) with the first device designed to stimulate new intestinal growth.
Introducing the Eclipse XL1.
The Eclipse XL1 is the first device-based therapy to regenerate healthy intestinal tissue using your body’s own biology. Our approach may offer patients a chance to naturally regrow their lost intestine.
Solving Short Bowel Syndrome (SBS)
Why Short Bowel Syndrome (SBS) Needs a New Solution.
SBS patients face a lifetime of complications – malnutrition, constant medical care, and limited quality of life. Current treatments are limited and invasive, often requiring long-term parenteral nutrition or transplant. We’re building a future where regeneration, not replacement, is the path forward.
Current SBS Treatments Fall Short
Existing options, like TPN, drug therapy, and surgery, don’t address the root problem, often come with severe side effects, and carry an extremely high cost.
Total Parenteral Nutrition (TPN)
- Lifelong Intravenous (IV) feeding and nutritional support
- Frequent hospitalizations for venous catheter-associated complications (infections, displacement, etc.)
- Toxicity often leading to end-stage liver disease
Drug Therapy (Teduglutide Injections)
- Daily injections
- Minimal improvement in absorption (max 20%)
- TPN/IV nutrition still required
Surgery and Intestinal Transplantation
- May not increase nutrient absorption
- May require lifelong immunosuppression drugs
- High risk of infection, rejection, death
Driven by Science. United by Purpose.
We’re a team of physicians, engineers, and entrepreneurs committed to changing the future of gastrointestinal care. Our mission: harness the body’s healing potential to restore what was lost.
Proudly Partnered
Our commitment to patient-centered innovation is driven by our partnerships with some of the leading healthcare organizations in the world. Eclipse Regenesis is proudly partnered with Boston Children’s Hospital, Cincinnati Children’s, UCLA Health, and Stanford Medicine. Together with our partners, we continue to pioneer the next generation of treatment for patients with Short Bowel Syndrome (SBS).
Join Us in Redefining the Future of GI Care.
Whether you’re a clinician, investor, or family seeking better options, we’re building a future where intestinal healing begins from within.